# OnCo record nct05356741 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05356741/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05356741", "NCT05356741" ;
  schema:name "To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers"@en ;
  schema:description "A phase 1/2 trial of VIR-5818 run by Vir Biotechnology, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05356741/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05356741> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/amx-818/> ;
  onco:companies <https://onco.cc/companies/amunix-pharmaceuticals/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/merck-kgaa/> .